



ATC 2017

Antibody Therapeutics Conference

Curriculum Vitae

Name: Yan Wu

Affiliation: Director and Principal Scientist, Genentech

Short Biography (maximum of 400 words):

Yan received her PhD from University of Colorado at Boulder in Molecular, Cellular and Developmental Biology, and had postdoc training at Genentech at Department of Molecular Oncology. Yan currently is Director and Principal Scientist at Department of Antibody Engineering. Yan is the head of Antibody Discovery group that support Genentech's R&D including all therapeutic areas. Yan has 20 years of industrial experience for drug discovery, and has 52 issued US patents and over 100 published US patents. Yan is the co-inventor of nine therapeutic antibodies that have entered clinical trial including the approved Tecentriq.

Speech Summary at ATC 2017

Speech Title: Therapeutic Antibody Discovery at Genentech

Speech Summary (200-400 words)

TECENTRIQ is the first approved anti-PDL1 medicine for people with specific types of advanced urothelial carcinoma and non-small cell lung cancer. The presentation will describe the work on Tececetriq and its combinations with other immune modulatory molecules. Case studies of using bi-specific antibodies at Genentech for different therapeutic areas will also be discussed.